Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is (GR-MD-02) belapectin galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
IPO Year:
Exchange: NASDAQ
Website: galectintherapeutics.com
4 - GALECTIN THERAPEUTICS INC (0001133416) (Issuer)
4 - GALECTIN THERAPEUTICS INC (0001133416) (Issuer)
4 - GALECTIN THERAPEUTICS INC (0001133416) (Issuer)
4 - GALECTIN THERAPEUTICS INC (0001133416) (Issuer)
4/A - GALECTIN THERAPEUTICS INC (0001133416) (Issuer)
4 - GALECTIN THERAPEUTICS INC (0001133416) (Issuer)
4 - GALECTIN THERAPEUTICS INC (0001133416) (Issuer)
4 - GALECTIN THERAPEUTICS INC (0001133416) (Issuer)
4 - GALECTIN THERAPEUTICS INC (0001133416) (Issuer)
4 - GALECTIN THERAPEUTICS INC (0001133416) (Issuer)
Recently, on June 20, 2024, Galectin Therapeutics Inc. saw an insider purchase by Director Freeman Kevin D. He bought $5,950 worth of shares, which amounted to 2,500 units at a price of $2.38 per share. This transaction increased his direct ownership by 10% to 28,469 units, as reported in the SEC Form 4. It's essential to analyze this insider purchase in the context of previous transactions within the company. On February 7, 2024, Uihlein Richard E was granted 23,256 shares, increasing his direct ownership by 0.23% to 10,268,751 units. Similarly, on the same date, Zordani Richard A. Jr. filed an SEC Form 4. Continuing the trend, a new insider, Carson Benjamin Sr, filed an SEC Form 3 on Febr
4 - GALECTIN THERAPEUTICS INC (0001133416) (Issuer)
4 - GALECTIN THERAPEUTICS INC (0001133416) (Issuer)
4 - GALECTIN THERAPEUTICS INC (0001133416) (Issuer)
4 - GALECTIN THERAPEUTICS INC (0001133416) (Issuer)
4 - GALECTIN THERAPEUTICS INC (0001133416) (Issuer)
3 - GALECTIN THERAPEUTICS INC (0001133416) (Issuer)
4/A - GALECTIN THERAPEUTICS INC (0001133416) (Issuer)
4 - GALECTIN THERAPEUTICS INC (0001133416) (Issuer)
4 - GALECTIN THERAPEUTICS INC (0001133416) (Issuer)
4 - GALECTIN THERAPEUTICS INC (0001133416) (Issuer)
HC Wainwright & Co. reiterated coverage of Galectin Therapeutics with a rating of Buy and set a new price target of $14.00 from $12.00 previously
The Dow Jones index closed lower by over 50 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform. Bespoke Extracts The Trade: Bespoke Extracts, Inc. (OTC:BSPK) CEO Michael Feinsod bought a total of 3,000 shares at an average price of $0.07. To acquire these shares, it cost around $210. What's Happening: The company's stock jumped around 51% o
Recently, on June 20, 2024, Galectin Therapeutics Inc. saw an insider purchase by Director Freeman Kevin D. He bought $5,950 worth of shares, which amounted to 2,500 units at a price of $2.38 per share. This transaction increased his direct ownership by 10% to 28,469 units, as reported in the SEC Form 4. It's essential to analyze this insider purchase in the context of previous transactions within the company. On February 7, 2024, Uihlein Richard E was granted 23,256 shares, increasing his direct ownership by 0.23% to 10,268,751 units. Similarly, on the same date, Zordani Richard A. Jr. filed an SEC Form 4. Continuing the trend, a new insider, Carson Benjamin Sr, filed an SEC Form 3 on Febr
The Dow Jones index closed higher by over 250 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform. Barnwell Industries The Trade: Barnwell Industries, Inc. (NYSE:BRN) 10% owner Sherwood Revocable Trust acquired a total of 52,150 shares an average price of $2.80. To acquire these shares, it cost around $146,263. What's Happening: On Feb. 20,
HC Wainwright & Co. analyst Ed Arce reiterates Galectin Therapeutics (NASDAQ:GALT) with a Buy and maintains $11 price target.
Data and Safety Monitoring Board (DSMB) recommends the continuation, without modifications, of the adaptive Phase 2b/3 NAVIGATE study of belapectin in metabolic dysfunction-associated steatohepatitis (MASH) liver cirrhosis Fifth positive recommendation further supports favorable tolerability and safety profile of belapectinInterim Phase 2b efficacy readout anticipated in Q4 2024
Gainers Candel Therapeutics (NASDAQ:CADL) stock increased by 27.6% to $8.17 during Friday's regular session. The company's market cap stands at $239.6 million. Galectin Therapeutics (NASDAQ:GALT) shares increased by 20.66% to $3.62. The company's market cap stands at $224.0 million. Ocugen (NASDAQ:OCGN) stock moved upwards by 17.88% to $1.78. The company's market cap stands at $456.7 million. As per the press release, Q4 earnings came out 3 days ago. Processa Pharma (NASDAQ:PCSA) shares moved upwards by 17.67% to $2.73. The market value of their outstanding shares is at $4.6 million. bioAffinity Technologies (NASDAQ:BIAF) stock rose 15.5% to $2.98. The market value of their outstanding
HC Wainwright & Co. analyst Ed Arce reiterates Galectin Therapeutics (NASDAQ:GALT) with a Buy and maintains $11 price target.
Galectin Therapeutics (NASDAQ:GALT) reported its Q3 earnings results on Monday, November 13, 2023 at 08:00 AM. Here's what investors need to know about the announcement. Earnings Galectin Therapeutics missed estimated earnings by 50.0%, reporting an EPS of $-0.24 versus an estimate of $-0.16. Revenue was down $0 from the same period last year. Past Earnings Performance Last quarter the company beat on EPS by $0.06 which was followed by a 7.38% increase in the share price the next day. To track all earnings releases for Galectin Therapeutics visit their earnings calendar here. This article was generated by Benzinga's automated content engine and reviewed by an editor.
NORCROSS, Ga., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Joel Lewis, Chief Executive Officer and Khurram Jamil, M.D., Chief Medical Officer, will be attending the H.C. Wainwright MASH Investor Conference being held October 7, 2024. Dr. Jamil will be sharing the latest updates on clinical programs and pipeline advancement on October 7, 2024 at 10:00 AM ET. The webcast of the presentation can be accessed here or through the Company's website on the Events & Presentation page of the investors section. About Galectin TherapeuticsGalectin Therapeutics is dedicated to d
NORCROSS, Ga., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Joel Lewis, Chief Executive Officer and Khurram Jamil, M.D., Chief Medical Officer, will be attending the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 in New York, NY. Dr. Jamil will be providing a company presentation on September 9, 2024 at 12:00 PM ET. The webcast of the presentation can be accessed here or through the Company's website on the Events & Presentation page of the investors section. Additionally, Galectin management team will be available for on
NAVIGATE trial on track for interim top-line analysis in December 2024 NORCROSS, Ga., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the quarter ended June 30, 2024. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said, "We continued to advance the NAVIGATE Phase 2b/3 trial of belapectin in the first half of 2024. We believe that belapectin can potentially offer a new medical treatment option for the increasing number of patients affected with MASH associated liver cirrhosis and portal hypertensi
NORCROSS, Ga., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced the appointment of Khurram Jamil, M.D., an accomplished senior executive with expertise in liver disease to Chief Medical Officer effective immediately. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said "We are very excited to elevate Dr. Jamil to Chief Medical Officer. After joining us in March 2024 as Vice President Clinical Development and Medical Director, Khurram has quickly integrated himself into our team and has led the management of our NAVIGATE clinical trial of belapectin
NORCROSS, Ga., June 04, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3, today announced that it will attend the EASL 2024 meeting and deliver a scientific presentation. The meeting will be held June 5-8, 2024, in Milan, Italy. "At this year's meeting we are again pleased to share important scientific information with the hepatology community. Through the knowledge captured from our belapectin program, we are adding knowledge on liver cirrhosis, a disease that dramatically affects the lives of our patients and has been neglected for far too long. This year we show that collagen content in liver biopsies of MAS
Fifth Data and Safety Monitoring Board (DSMB) meeting recommended the continuation, without modifications, of the Phase 2b/3 NAVIGATE study of belapectin in liver cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH)NAVIGATE trial remains on track for interim top-line readout late in the fourth quarter of 2024 NORCROSS, Ga., May 15, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the quarter ended March 31, 2024. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said "This quarter we remai
NORCROSS, Ga., May 13, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be attending and presenting at the H.C. Wainwright 2nd Annual BioConnect Investor Conference. Detailed information about the presentation is below. H.C. Wainwright 2nd Annual BioConnect Investor Conference Format: Fireside chat Date and time: May 20, 2024 at 4:00 PM ET Location: Nasdaq World Headquarters, New York City Webcast: https://journey.ct.events/view/e36631f4-3c58-4887-8d5b-1e7f6ce3bfe8 Galectin management team will be available for one-on-one meetings during the conferences. Interested
Data and Safety Monitoring Board (DSMB) recommends the continuation, without modifications, of the adaptive Phase 2b/3 NAVIGATE study of belapectin in metabolic dysfunction-associated steatohepatitis (MASH) liver cirrhosisFifth positive recommendation further supports favorable tolerability and safety profile of belapectinInterim Phase 2b efficacy readout anticipated in Q4 2024 NORCROSS, Ga., April 09, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3, today reported the positive outcome of its fifth independent data and safety monitoring board (DSMB) meeting for NAVIGATE, its seamless, adaptive, Phas
NORCROSS, Ga., March 29, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2023. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said "We have been focused on advancing our Metabolic Dysfunction-Associated Steatohepatitis (MASH, formerly known as NASH) cirrhosis program. We completed enrollment and randomization for the NAVIGATE Phase 2b/3 trial in 2023, and belapectin has consistently shown an encouraging safety profile, which was determined by our independent Data and Saf
NORCROSS, Ga., March 12, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced the appointment of Khurram Jamil, M.D. as Vice President, Clinical Development. Dr. Jamil brings to Galectin almost two decades of experience in clinical development across the biotechnology industry. "We are pleased to welcome Khurram to the Galectin team at such a meaningful time of our development program" said Pol F. Boudes, M.D., Chief Medical Officer. "His breadth of expertise in clinical development, especially in hepatology and liver cirrhosis, along with his experience with regulatory interactions a
NORCROSS, Ga., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced the appointment of Khurram Jamil, M.D., an accomplished senior executive with expertise in liver disease to Chief Medical Officer effective immediately. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said "We are very excited to elevate Dr. Jamil to Chief Medical Officer. After joining us in March 2024 as Vice President Clinical Development and Medical Director, Khurram has quickly integrated himself into our team and has led the management of our NAVIGATE clinical trial of belapectin
NORCROSS, Ga., March 12, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced the appointment of Khurram Jamil, M.D. as Vice President, Clinical Development. Dr. Jamil brings to Galectin almost two decades of experience in clinical development across the biotechnology industry. "We are pleased to welcome Khurram to the Galectin team at such a meaningful time of our development program" said Pol F. Boudes, M.D., Chief Medical Officer. "His breadth of expertise in clinical development, especially in hepatology and liver cirrhosis, along with his experience with regulatory interactions a
NORCROSS, Ga., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that the Company has recently expanded its management team with multiple key leadership appointments, including Dakshina Reddy, MSM, as Executive Director, Regulatory Affairs; Ezra R. Lowe, Ph.D., as Executive Director, Clinical and Preclinical Pharmacology; Marla Mills-Wilson as Executive Director, Clinical Operations; and Jessica Kopaczewski as Associate Director, Clinical Operations. These strategic appointments strengthen the company's clinical, regulatory, and operational efforts across its ongoing programs in c
SC 13D/A - GALECTIN THERAPEUTICS INC (0001133416) (Subject)
8-K - GALECTIN THERAPEUTICS INC (0001133416) (Filer)
8-K - GALECTIN THERAPEUTICS INC (0001133416) (Filer)
10-Q - GALECTIN THERAPEUTICS INC (0001133416) (Filer)
8-K - GALECTIN THERAPEUTICS INC (0001133416) (Filer)
8-K - GALECTIN THERAPEUTICS INC (0001133416) (Filer)
10-Q - GALECTIN THERAPEUTICS INC (0001133416) (Filer)
8-K - GALECTIN THERAPEUTICS INC (0001133416) (Filer)
10-K - GALECTIN THERAPEUTICS INC (0001133416) (Filer)
8-K - GALECTIN THERAPEUTICS INC (0001133416) (Filer)
8-K - GALECTIN THERAPEUTICS INC (0001133416) (Filer)
NAVIGATE trial on track for interim top-line analysis in December 2024 NORCROSS, Ga., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the quarter ended June 30, 2024. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said, "We continued to advance the NAVIGATE Phase 2b/3 trial of belapectin in the first half of 2024. We believe that belapectin can potentially offer a new medical treatment option for the increasing number of patients affected with MASH associated liver cirrhosis and portal hypertensi
Fifth Data and Safety Monitoring Board (DSMB) meeting recommended the continuation, without modifications, of the Phase 2b/3 NAVIGATE study of belapectin in liver cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH)NAVIGATE trial remains on track for interim top-line readout late in the fourth quarter of 2024 NORCROSS, Ga., May 15, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the quarter ended March 31, 2024. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said "This quarter we remai
NORCROSS, Ga., March 29, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2023. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said "We have been focused on advancing our Metabolic Dysfunction-Associated Steatohepatitis (MASH, formerly known as NASH) cirrhosis program. We completed enrollment and randomization for the NAVIGATE Phase 2b/3 trial in 2023, and belapectin has consistently shown an encouraging safety profile, which was determined by our independent Data and Saf
NORCROSS, Ga., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended September 30, 2023. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the U.S. Securities and Exchange Commission and is available at www.sec.gov. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said: "Recently, two significant events occurred that we believe demonstrate confidence in our ongoing mission to bring to market a therapy for NASH cirrhosis patients w
NORCROSS, Ga., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended June 30, 2023. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the U.S. Securities and Exchange Commission and is available at www.sec.gov. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said: "We are increasingly optimistic as we oversee and manage our adaptively designed Phase 2b/3 NAVIGATE trial for the prevention of esophageal varices in patients with NASH
NORCROSS, Ga., May 15, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended March 31, 2023. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the U.S. Securities and Exchange Commission and is available at www.sec.gov. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said: "Our entire team is actively engaged in oversight and management of our adaptively designed Phase 2b/3 NAVIGATE trial for the prevention of esophageal varices in patients
NORCROSS, Ga., March 30, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2022. These results are included in the Company's Annual Report on Form 10-K, which has been filed with the U.S. Securities and Exchange Commission and is available at www.sec.gov. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said: "As previously reported, we completed recruitment in late December 2022 and randomization by the end of February 2023 in our adaptively designed Phase 2b/3 NAVIGATE trial for
NORCROSS, Ga., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended September 30, 2022. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the U.S. Securities and Exchange Commission and is available at www.sec.gov. Joel Lewis, Chief Executive Officer and President, stated: "The Company made outstanding progress this quarter. In addition to securing the largest financing in the Company's history, which extended our cash runway for planned trial expenditures t
NORCROSS, Ga., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended June 30, 2022. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the U.S. Securities and Exchange Commission and is available at www.sec.gov. Joel Lewis, Chief Executive Officer and President, stated: "Our team made significant progress on a number of fronts this quarter. The most consequential action for the Company undoubtedly was finalizing a $60 million line of credit facility from Richa
NORCROSS, Ga., May 16, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended March 31, 2022. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the U.S. Securities and Exchange Commission and is available at www.sec.gov. Dr. Pol Boudes, Chief Medical Officer, stated: "As we hear more about difficulties of reading and interpreting liver biopsies in pre-cirrhotic NASH, the feedback we get from our investigators reinforces our belief that using the prevention of esophage